SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma
BioMed Research International · 2026-01 · 2026 (1)
DOI: 10.1155/bmri/4420962 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, online erschienen am 09.04.2026. Verfasst von Şule Çalışkan Kamış und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Osteosarcoma, Sarcoma, Ewing. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study is aimed at evaluating the relationship between preoperative 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F‐FDG PET/CT) findings and histopathological necrosis rates following chemotherapy in patients diagnosed with osteosarcoma (OST) and Ewing sarcoma (EWS).
Methods
Patients diagnosed with OST and EWS between 2017 and 2023 were retrospectively analyzed. Data recorded included preoperative 18 F‐FDG PET/CT findings, demographic characteristics, histopathological diagnosis, maximum standardized uptake value at diagnosis (SUVmax1), maximum standardized uptake value after neoadjuvant chemotherapy (SUVmax2), the SUVmax change ratio (SUVmax2/SUVmax1 = SCR), and the percentage of tumor necrosis in resected specimens.
Results
A total of 49 patients (33 OST and 16 EWS) were included, consisting of 22 females (44.9%) and 27 males (55.1%) with a median age of 12 years (range: 4–20). Median SUVmax1, SUVmax2, and SCR values were 6.8 (0–22.5), 2.5 (0–9.42), and 0.38 (0–1.44), respectively. The median tumor necrosis percentage was 20% (range: 0–100). Stratification according to SUVmax2 (< 2.5 vs. ≥ 2.5) revealed no significant difference in necrosis percentage ( p = 0.234). No significant correlation was observed between SCR and necrosis percentage ( p = 0.102). However, a significant inverse correlation was found between SUVmax2 and necrosis percentage in the overall cohort ( p = 0.040, r = –0.295), which was more pronounced in OST patients ( p = 0.014, r = –0.426).
Conclusion
18 F‐FDG PET/CT is a valuable imaging modality for predicting histopathological response in solid tumors. Consistent with adult studies, our findings demonstrate that post‐NACT FDG uptake is inversely correlated with tumor necrosis percentage, particularly in pediatric OST patients. These results highlight the potential of 18 F‐FDG PET/CT as a noninvasive prognostic tool to assist in early identification of poor responders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr.
- Department of Nuclear Medicine, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr.
- Department of Medical Pathology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr.
ORCID-Profile: Şule Çalışkan Kamış, Metin Çil, Emel Koçyiğit Deveci, Zeynel Abidin Taş, Begül Yağcı
Zitieren
APA
Kamış, Ş. Ç., Çil, M., Deveci, E. K., Taş, Z. A., & Yağcı, B. (2026). SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma. BioMed Research International, 2026(1). https://doi.org/10.1155/bmri/4420962
Vancouver
Kamış ŞÇ, Çil M, Deveci EK, Taş ZA, Yağcı B. SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma. BioMed Research International. 2026;2026(1). doi:10.1155/bmri/4420962
BibTeX
@article{Kam2026,
author = {Kamış, Şule Çalışkan and Çil, Metin and Deveci, Emel Koçyiğit and Taş, Zeynel Abidin and Yağcı, Begül},
title = {SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma},
journal = {BioMed Research International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/bmri/4420962}
}
EUVIMED